Home > News > NUCRYST Pharmaceuticals begins Phase 2 clinical trial
December 4th, 2003
NUCRYST Pharmaceuticals begins Phase 2 clinical trial
Abstract:
NUCRYST Pharmaceuticals Corp., a subsidiary of The Westaim Corporation, today announced that it has
begun its first Phase 2 human clinical trial of a topical cream formulation of its nanocrystalline silver. The investigational drug (NPI 32101) is being studied for atopic dermatitis, a form of eczema, and other skin conditions and represents a biological application of nanotechnology.
Source:
PRNewswire
Bookmark:
| Related News Press |
Nanomedicine
New molecular technology targets tumors and simultaneously silences two ‘undruggable’ cancer genes August 8th, 2025
New imaging approach transforms study of bacterial biofilms August 8th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||